{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.15","upperLimit":"0.57","value":"0.33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Proportion of patients who had RECIST documented partial or complete response. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded). Each lesion must be ≥ 10 mm when measured by CT and MRI; or ≥ 20 mm when measured by conventional techniques, including plain x-ray. Response was documented per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Galunisertib: Galunisertib 150mg po BID day 4-17\n\nPaclitaxel: Paclitaxel 175 mg/m2 over 3 hours\n\nCarboplatin: IV day 1 Carboplatin AUC 6\\* over 1 hour (or 5\\* if prior radiation therapy)","id":"OG000","title":"Paclitaxel/Carboplatin + Galunisertib"}],"paramType":"NUMBER","populationDescription":"Patients who received four cycles of study drugs","reportingStatus":"POSTED","timeFrame":"within three years of study entry","title":"Objective Response","type":"SECONDARY","unitOfMeasure":"proportion of patients with CR/PR"}